BEAM base editing platform advances toward commercialization
BEAM says its base editing platform enables precise, durable genetic corrections across multiple diseases, citing strong efficacy and safety data in alpha-1 antitrypsin deficiency and noting regulatory alignment for accelerated approval.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.